Trial · NCT02121756
Outcomes15
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Monocyte and Macrophage Activation Assessed as Change in Plasma Levels of sCD14 From Baseline to Week 12 | Baseline to week 12 | 35 participants were included in the as-treated (AT) analysis (17 Dipyridamole, 18 placebo); 4 Dipyridamole (1 adverse event 1 protocol deviation, 2 investigator discretion) and 1 placebo (change in antiretroviral therapy) participants were excluded from the primary AT analysis. | pg/ml | MEDIAN |
| PRIMARY | Monocyte and Macrophage Activation Assessed as Change in Plasma Levels of sCD163 From Baseline to Week 12 | baseline to week 12 | 35 participants were included in the as-treated (AT) analysis (17 Dipyridamole, 18 placebo); 4 Dipyridamole (1 adverse event 1 protocol deviation, 2 investigator discretion) and 1 placebo (change in antiretroviral therapy) participants were excluded from the primary AT analysis. | ng/ml | MEDIAN |
| PRIMARY | Systemic Inflammation Assessed as Change in IL-6 Plasma Levels From Baseline to Week 12 | baseline to week 12 | 35 participants were included in the as-treated (AT) analysis (17 Dipyridamole, 18 placebo); 4 Dipyridamole (1 adverse event 1 protocol deviation, 2 investigator discretion) and 1 placebo (change in antiretroviral therapy) participants were excluded from the primary AT analysis. | pg/ml | MEDIAN |
| SECONDARY | Immune System Activation as Measured by the Proportion of CD8+ T Cells Co-expressing CD69 and CD25 After 12 Weeks of Dipyridamole Treatment Compared to Placebo | Baseline to week 12 | Per protocol, participants randomized to placebo were crossed over to DP after week 12. | proportion of CD8+ T cells | MEDIAN |
| SECONDARY | Safety and Tolerability of Dipyridamole Assessed as the Number of Participants With Grade 2 or Higher Adverse Events or Treatment Discontinuations | First 12 weeks of dipyridamole treatment | All enrolled participants | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Immune System Activation Assessed as the Change in the Proportion of Cycling CD4+ T Cells as Measured by Ki-67 Expression at Baseline and After Treatment With Dipyridamole | Baseline to week 12 | Per protocol, participants randomized to placebo were crossed over to DP after week 12. | proportion of cycling CD4+ T Cells | MEDIAN |
| SECONDARY | Immune System Activation as Measured by the Proportion of CD4+ T Cells Co-expressing HLA-DR and CD38 After 12 Weeks of Dipyridamole Treatment Compared to Placebo | Baseline to week 12 | Per protocol, participants randomized to placebo were crossed over to DP after week 12. | proportion of CD4+ T cells | MEDIAN |
| SECONDARY | Immune System Activation as Measured by the Proportion of CD8+ T Cells Co-expressing HLA-DR and CD38 After 12 Weeks of Dipyridamole Treatment Compared to Placebo | Baseline to week 12 | Per protocol, participants randomized to placebo were crossed over to Dipyridamole after week 12. | proportion of CD8+ T cells | MEDIAN |
| SECONDARY | Immune System Activation Assessed by the Proportion of CD4+ T Cells Co-expressing CD69 and CD25 After 12 Weeks of Dipyridamole Treatment to Placebo | Baseline to week 12 | Per protocol, participants randomized to placebo were crossed over to Dipyridamole after week 12. | proportion of CD4+ T cells | MEDIAN |
| SECONDARY | Cellular Immune Activation: Change in the Proportion of Cycling CD8+ T Cells | Baseline to week 12 | Per protocol, participants randomized to placebo were crossed over to Dipyridamole after week 12. | proportion of cycling CD8+ T Cells | MEDIAN |
| SECONDARY | Systemic Inflammatory Biomarkers: Change in the Levels of sTNFαR | Baseline to week 12 | Per protocol, participants randomized to placebo were crossed over to Dipyridamole after week 12. | pg/ml | MEDIAN |
| SECONDARY | Systemic Inflammatory Biomarkers: Change in the Levels of TNFα | Baseline to week 12 | Per protocol, participants randomized to placebo were crossed over to Dipyridamole after week 12. | pg/ml | MEDIAN |
| SECONDARY | Systemic Inflammatory Biomarkers: Change in the Levels of hsCRP | Baseline to week 12 | Per protocol, participants randomized to placebo were crossed over to Dipyridamole after week 12. | ng/dl | MEDIAN |
| SECONDARY | Coagulation Biomarkers: Change in the Levels of D-dimer | Baseline to week 12 | Per protocol, participants randomized to placebo were crossed over to Dipyridamole after week 12. | mcg/ml | MEDIAN |
| SECONDARY | Changes in Brachial Artery Flow-mediated Dilation (FMD) | Baseline to week 12 | Per protocol, participants randomized to placebo were crossed over to DP after week 12. | percentage change at tmax | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02121756/outcomes